Trop2-targeted immunoPET Imaging of Solid Tumors

Launched by RENJI HOSPITAL · Feb 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called Trop2-targeted immunoPET/CT, which aims to help doctors better see and diagnose solid tumors like bladder cancer, prostate cancer, and lung cancer, among others. By using this advanced imaging method, researchers hope to understand how well it works in identifying these types of cancers, which may lead to improved diagnosis and treatment options for patients.

To participate in the trial, you need to be between 18 and 75 years old and have a confirmed or suspected diagnosis of one of the solid tumors mentioned. You'll also need to be able to provide informed consent, meaning you understand the study and agree to participate. Participants can expect to undergo special imaging tests as part of the study, and the trial is currently recruiting individuals. It's important to note that pregnant individuals and those with severe liver or kidney issues, or allergies to specific imaging agents, won't be eligible for this trial. This study could potentially lead to better ways to diagnose and manage various cancers in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18-75 year-old and of either sex
• • Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging;
• • Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.
• Exclusion Criteria:
• • Pregnancy；
• • Severe hepatic and renal insufficiency;
• • Allergic to single-domain antibody radiopharmaceuticals.